Fennec Pharmaceuticals

Yahoo Finance • 8 days ago

Adherex Technologies’ PEDMARK Push Targets Larger AYA Market After Record Quarter

Key Points Interested in Adherex Technologies Inc.? Here are five stocks we like better. Fennec Pharmaceuticals said PEDMARK is seeing stronger commercial traction, with first-quarter 2026 revenue reaching a record $15.1 million as the co... Full story

Yahoo Finance • 9 days ago

Fennec Pharmaceuticals Announces New Research Supporting Integration and Use of PEDMARK® at the 2026 ASCO Annual Meeting

~ Growing Independent Research Efforts are Expanding Evidence Base Around How PEDMARK® (sodium thiosulfate injection) May Benefit Broader and More Diverse Patient Populations ~ ~ Real-World Evidence Shows Administration of PEDMARK® Approx... Full story

Yahoo Finance • 17 days ago

Adherex Technologies Q1 Earnings Call Highlights

Key Points Interested in Adherex Technologies Inc.? Here are five stocks we like better. Fennec Pharmaceuticals reported strong Q1 2026 results, with net product sales rising about 73% year over year to $15.1 million and positive operatin... Full story

Yahoo Finance • 17 days ago

Fennec Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update

~ Achieved First Quarter 2026 Total Net Revenues of $15.1 Million, Up 73% Year Over Year ~ ~ Field Sales Expansion Showing Early Signs of Positive Results with Record PEDMARK® Demand in April 2026 ~ ~ Initiated Third Institution-Led Clin... Full story

Yahoo Finance • last month

Fennec Pharmaceuticals Announces Acceptance of Abstracts at the 2026 ASCO Annual Meeting

– Data from Four Studies Spotlight Rising Clinical Interest & Urgency to Address Cisplatin-Induced Hearing Loss and Its Lasting Impact on Patients – RESEARCH TRIANGLE PARK, N.C., April 21, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals... Full story

Yahoo Finance • 2 months ago

Fennec Pharmaceuticals Announces Investigator-Sponsored Study to Be Conducted by University of Arizona Cancer Center

~ University of Arizona Cancer Center Initiating Study to Explore Use of PEDMARK® in AYA & Adult Patients with Solid Tumors Receiving Cisplatin ~ ~ This New Study and Other Independent, Institution-Led Research Continues to Expand Real-Wo... Full story

Yahoo Finance • 2 months ago

Fennec Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

RESEARCH TRIANGLE PARK, N.C., March 31, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today announced that on March 17, 2026, the Compensatio... Full story

Yahoo Finance • 2 months ago

Adherex Technologies Q4 Earnings Call Highlights

Adherex Technologies logo Fennec Pharmaceuticals reported record commercial growth for PEDMARK during its fourth quarter and full year 2025 earnings call, highlighting expanding adoption in both new and existing accounts, improved patient... Full story

Yahoo Finance • 2 months ago

Fennec Pharmaceuticals to Report Full Year and Fourth Quarter 2025 Financial Results on March 24, 2026

RESEARCH TRIANGLE PARK, N.C., March 18, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its full year and f... Full story

Yahoo Finance • 3 months ago

Water Giant With $7 Billion in Revenue Draws $7.5 Million Investment, and Shares Are Surging This Year

Key Points Solas Capital Management added 460,619 shares of PRMB in the fourth quarter. The quarter-end position value increased by $7.53 million as a result. PRMB now accounts for 4.27% of fund AUM.10 stocks we like better than Primo Bra... Full story

Yahoo Finance • 3 months ago

Payments Stock Down 30% Draws $6 Million Bet as Company Posts $4 Billion in Revenue

On February 17, 2026, Solas Capital Management disclosed a new position in Euronet Worldwide(NASDAQ:EEFT), acquiring 73,494 shares in the fourth quarter. The shares were worth $5.59 million at quarter’s end. What happened According to a... Full story

Yahoo Finance • 3 months ago

Fennec Pharmaceuticals Presents Real World Data Supporting the Integration and Clinical Use of PEDMARK® in Treating Adults with Head & Neck Cancers

– Administration of PEDMARK® Approximately Six Hours After Cisplatin was Shown to Be Safe & Easily Integrated into Care for Adults with Head & Neck Cancers (HNC) – – Early Signals of Hearing Preservation Highlight the Potential of PEDMARK... Full story

Yahoo Finance • 6 months ago

Fennec Pharmaceuticals Announces Positive Topline Results From Investigator-Initiated Clinical Study of PEDMARK® in Japan to Reduce Cisplatin-Induced Hearing Loss

– Study, Which Enrolled 27 Patients, Met Primary Endpoint with a Significant Reduction in Hearing Loss in 3-18 Year Old Patients who Received PEDMARK® when Compared with Historically Reported Rates of Hearing Loss in Patients Receiving Cis... Full story

Yahoo Finance • 6 months ago

Fennec Pharmaceuticals to Participate in Piper Sandler 37th Annual Healthcare Conference

RESEARCH TRIANGLE PARK, N.C., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will participate in a fireside ch... Full story

Yahoo Finance • 6 months ago

Fennec Pharmaceuticals Announces Completion Of Full Debt Redemption

RESEARCH TRIANGLE PARK, N.C., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today announced it has repurchased and redeemed all of... Full story

Yahoo Finance • 6 months ago

Fennec Pharmaceuticals Announces Closing of Offering of Common Shares

RESEARCH TRIANGLE PARK, N.C., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today announced the closing of its underwritten register... Full story

Yahoo Finance • 7 months ago

Fennec Pharmaceuticals plans share offering in Canada to raise up to $5 million

* Fennec Pharmaceuticals (FENC [https://seekingalpha.com/symbol/FENC])  intends [https://seekingalpha.com/pr/20307705-fennec-pharmaceuticals-announces-private-offering-of-common-shares-in-canada]to engage in a non-brokered offering of it... Full story

Yahoo Finance • 7 months ago

Fennec Pharmaceuticals Announces Private Offering of Common Shares in Canada

RESEARCH TRIANGLE PARK, N.C., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today announced that it intends to engage in a non-broke... Full story

Yahoo Finance • 7 months ago

Fennec Pharmaceuticals Announces Pricing of Offering of Common Shares

RESEARCH TRIANGLE PARK, N.C., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today announced the pricing of its underwritten register... Full story

Yahoo Finance • 7 months ago

Fennec Pharmaceuticals announces proposed offering of common shares

* Fennec Pharmaceuticals (NASDAQ:FENC [https://seekingalpha.com/symbol/FENC]) stated [https://seekingalpha.com/pr/20307363-fennec-pharmaceuticals-announces-proposed-offering-of-common-shares] on Thursday that it would sell its common sha... Full story